Ruxolitinib cas 941678-49-5; INCB018424; Ruxolitinib (INCB018424); (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile; INCB-018424; INCB 018424; UNII-82S8X8XX8H;

China Ruxolitinib API Suppliers

Ruxolitinib is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.

Ruxolitinib is a Janus kinase inhibitor that is used in the treatment of intermediate or high risk myelofibrosis and resistant forms of polycythemia vera and graft-vs-host disease. Ruxolitinib is associated with transient and usually mild elevations in serum aminotransferase during therapy and to rare instances of self-limited, clinically apparent idiosyncratic acute liver injury and to cases of reactivation of hepatitis B in susceptible individuals.

Ruxolitinib API Cas 941678-49-5,INCB018424 Ruxolitinib Offering,Jakafi Roxolitinib Offering.

Min.Order	Unit Price
1 Kilogram	USD 1 / Kilogram

Min.Order	Unit Price
1 Kilogram	USD 1 / Kilogram

Min.Order	Unit Price
1 Kilogram	USD 1 / Kilogram

Ruxolitinib API

Ruxolitinib API Cas No.941678-49-5

Ruxolitinib API INCB018424 Cas 941678-49-5 Offering

Ruxolitinib API Cas 941678-49-5

Ruxolitinib API Cas No.941678-49-5

Ruxolitinib API INCB018424 Cas 941678-49-5 Offering

Ruxolitinib API Cas 941678-49-5

China Ruxolitinib API Suppliers